Magnetic Resonance Imaging Biomarker

Magnetic resonance imaging biomarker enables non-invasive lesion assessment predicting treatment response. Gadolinium enhancement indicates blood-brain barrier disruption. Diffusion-weighted imaging detects cellular density changes. Perfusion imaging quantitates blood flow. Volumetric analysis tracks lesion size changes.

Regulatory acceptance as surrogate endpoint streamlines approval. Clinical correlation validates MRI biomarker. Standardisation enables cross-trial comparison. Post-approval monitoring employs MRI surveillance. Emerging molecular imaging improves specificity.